HBOT Conversations:
Laurie Anderson (Part 1)

Healing COVID with HBOT

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.

Subscribe. Join the discussion. Share the hope.

Watch the Podcast

We are thrilled to have Dr. Laurie Anderson join us at the HBOT News Network. Dr. Laurie used Hyperbaric Oxygen Therapy to heal from a very serious COVID illness.

Dr. Laurie explains her background to the audience and that she received treatment in Raleigh, NC at the Extivita clinic. Her background is important and intriguing.  Dr. Laurie is a Pharmacist by training, a PharmD. While she has done some clinical work in the past, her passion lies in the safety of clinical studies. She focuses on early phase clinical study work, designing risk mitigation strategies for first time in human studies. Dr. Laurie explained that in her line of work she looks at the risk profile of the assets coming out, the design risk mitigation strategies, and then follows them in the clinic to track them to help ensure that they know what’s safe and what isn’t. Essentially, she is part of the team that helps determine if certain drugs are safe and effective.

di Girolamo explains that when he first started looking at hyperbarics, he was personally trying to understand if it was indeed safe and effective.  He found that it was, and was blown away that everyone wasn’t using it. This opened the door to Dr. Laurie telling her story of COVID healing with HBOT, and what led her to Extivita.

Dr. Laurie explains that she has a history of lyme diesease, and worked really hard not to get COVID in fear that she would struggle with complete healing.  She had been vaccinated and boostered, and when she did get COVID she became very ill. In addition to losing her sense of smell and taste, she had a relentless cough, really awful fatigue, and some shortness of breath that that just wasn’t improving.  She ended up on medical leave because she could not work, and when she started to reach the end of the medical leave she still was not improving. Dr. Laurie talked to the naturopath who had been following her for many years, and her naturopath suggested NAD infusions. Dr. Laurie had never heard of NAD infusions before, so she started to read about them and who does them locally in the Raleigh, NC area.  That’s when Dr. Laurie was introduced to the Extivita clinic.

Dr. Laurie came to Extivita to start NAD infusions, but was also encouraged to try Hyperbaric Oxygen Therapy to heal from COVID.  The clinic explained that they are seeing really great success using hyperbarics for COVID long-hauler patients. Dr. Laurie was hesitant due to her claustrophobia, but in the end she decided it was worth a try.  She educated herself on HBOT, and found that there wasn’t a reason why she shouldn’t do it.  She was desperate to heal from the COVID infection. So, she committed to 20 dives, 4 days a week and had phenomenal results; claiming significant improvement after only ten dives.

“I got to say, I was kind of blown away because I had been battling with no improvement for long enough to be concerned, and I came in and I think it was about maybe five or six dives in, and my taste and smell started returning. It was completely gone. And I started to see a change probably in maybe eight, nine or ten, that my cough started going away. I would say by 12 or 13 dives, I felt healed, I felt recovered and even better than I felt going in [the way I felt before getting COVID].”

Dr. Laurie exclaimed that she noticed a positive difference in her energy and sleep almost immediately.  She was more restful, and she said she pays close attention to those things because her history with chronic illness.

“I just could tell a difference. And in my energy, mainly. My energy level and my sleep really shifted, which was a real gift.”

Dr. Laurie even shared her story in an Extivita testimonal, hopeful that others can also discover the powerful combination of oxygen and pressure to heal from COVID.

 

Stay tuned next week for Part 2 of Dr. Laurie’s podcast. We will talk with her about some other benefits of HBOT, and we’ll pick her brain on clinical trials involving hyperbaric oxygen therapy.

 

Guests

Elena Schertz, NP

Dr. Laurie Anderson, Pharm.D.

Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF).  Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center.  For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.

Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing.  She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health.  Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.

When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.

Subscribe Now, It’s Free!

[contact-form-7 id="65934" title="Subscribe"]

Recent HBOT News

Clinical Trial – HBOT Global Functioning After Stroke

Stroke is one of the leading causes of disability and death in North America and Europe. Up
to 30% of stroke survivors never recuperate completely and suffer from loss of function and
poor quality of life. To improve recovery after stroke, innovative interventions should be a
priority.

Hyperbaric oxygen therapy (HBOT) is an intermittent inhalation of 100% oxygen in a hyperbaric
chamber at a pressure higher than 1 absolute atmosphere (ATA). There is a growing body of
evidence that HBOT can enhance ability of brain to changes its structure (neuroplasticity) in
order to recover. Exercise program during HBOT can augment the effect. Although, recent
randomized controlled trials in patients with chronic brain injury showed promising results,
there are no studies demonstrating combine effect HBOT and exercise rehabilitation program on
stroke recovery.

The proposed study investigates feasibility, safety and efficacy of using a combination of
HBOT and exercise program to improve arm function recovery in chronic stroke patients. In
this pilot randomized control trial, investigators will compare the combination of HBOT and
the focused rehabilitation exercise program versus exercise program alone on recovery of arm
function in patients with chronic stroke.

Clinical Trial – Hyperbaric Oxygen Therapy and Acute Kidney Injury

Kidney injury is a serious complication of cardiac surgery that occurs in up to 30% of
patients and increases the risk of adverse outcomes. Kidney injury initiates when oxygen
supply to the kidney drops below levels that are needed for normal cellular function, causing
tissue oxygen deficiency (hypoxia), activation of the inflammatory cascade, and oxidative
stress. Together, these events further impair tissue oxygenation, culminating in impaired
kidney function due to cellular injury and death.

There are no effective therapies for kidney injury after cardiac surgery, but there is
evidence that recovery is possible if the processes of injury – i.e., impaired oxygen
delivery, increased inflammatory response, and oxidative stress – are ameliorated soon after
the onset of injury. Hyperbaric oxygen therapy (HBOT) – which entails the intermittent
inhalation of 100% oxygen in a hyperbaric chamber at a pressure higher than one absolute
atmosphere (> 760 mmHg) – has been shown to positively affect all of these processes (i.e.,
to improve tissue oxygenation, reduce inflammation, and reduce oxidative stress). Thus, we
hypothesized that HBOT will reduce the severity of kidney injury after cardiac surgery if it
is initiated soon after onset of injury. This hypothesis has not been tested in humans, but
is supported by animal studies.

In this first-in-human, unblinded, controlled pilot trial, 20 adult patients who develop
severe kidney injury soon after cardiac surgery will be randomized (after obtaining informed
consent from the patient or surrogate) to standard-of-care or early HBOT. Severe kidney
injury will be defined as a ≥30% drop in kidney function within 6 hours of surgery (as
determined by change in creatinine from before surgery to Intensive Care Unit (ICU)
admission). This degree of injury occurs in ~ 2% of patients and is associated with a 12-fold
increase in the risk of complete kidney failure (requiring dialysis) or death. Patients will
be excluded if they have any relative or absolute contraindications to HBOT (e.g., severe
ventricular dysfunction, ventricular assist device, severe respiratory dysfunction,
pneumothorax, bronchospasm).